-
Mashup Score: 0Addition of Venetoclax to Lenalidomide and Rituximab Therapy for Patients With Previously Untreated MCL - 5 month(s) ago
Kami J. Maddocks, MD, discusses results from a single-arm study on the addition of venetoclax to a lenalidomide and rituximab regimen for patients with previously untreated mantle cell lymphoma.
Source: www.hmpgloballearningnetwork.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut - 5 month(s) ago
Key Points. Time-limited triple therapy leads to high rates of undetectable minimal residual disease and sustained remissions in high-risk CLL.Adverse events oc
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents - 6 month(s) ago
Blood Cancer Journal – Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents
Source: www.nature.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Marlise Luskin,MD, MSCE [slides]-Venetoclax and BCL2 Inhibitors - 6 month(s) ago
Marlise Luskin,MD, MSCE- Medical Oncology- Dana-Farber/Mass General Brigham Hematology/Oncology Fellowship Program and education director for the adult leukemia program. The presentation focused on the use of the drug venetoclax (and its related drugs) in the treatment of acute lymphoblastic leukemia (ALL), particul…
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Fixed-Duration, Triple-Combination Therapy Shows Efficacy for Patients With High-Risk CLL | ASH Clinical News | American Society of Hematology - 6 month(s) ago
Anna Azvolinsky, PhD, is a freelance medical and science journalist based in New York City. The triple combination of obinutuzumab, ibrutinib, and venetoclax has shown a relatively high response rate among previously untreated patients with high-risk chronic lymphocytic leukemia (CLL), according to study results published in Blood. The limited-duration triple combination therapy achieved a complete response of 58.5% in the phase II CLL2-GIVe trial of 41 patients with high-risk CLL. Most adverse events
Source: ashpublications.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1A Novel Type of Monocytic Leukemia Stem Cell Revealed by the Clinical Use of Venetoclax-Based Therapy - 6 month(s) ago
Analyses of leukemia stem cells (LSC) in human acute myeloid leukemia (AML) revealed a type of monocytic LSC, distinct from primitive LSCs, that is responsible for the relapse/refractory response of some patients with AML treated with the BCL2 inhibitor venetoclax.
Source: aacrjournals.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 18How to Treat Chronic Lymphocytic Leukemia (CLL) with Dr. Jeff Sharman – ONC Brothers - 7 month(s) ago
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and…
Source: oncbrothers.comCategories: Latest Headlines, Partners & KOLsTweet
-
Mashup Score: 0Branko Cuglievan, MD [slides]- AML: Insights on Menin Inhibition - 7 month(s) ago
Branko Cuglievan, MD- Assistant Professor, Department of Pediatrics Patient Care, Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX – Section Chief, Leukemia/Lymphoma, Department of Pediatrics Patient Care, Division of Pediatrics, The University of Texas MD Anderson Cancer C…
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🔍 Uncover Pediatric #AML treatment insights with Branko Cuglievan, MD: Menin inhibition, #inotusumab, #venetoclax, and collaborative strides in pediatric & adult oncology for improved outcomes.[video][slides] https://t.co/YP3hFDyFbv @_MDEducation @Ryan_fitzpatric @MDAndersonNews https://t.co/fdaAxQqrmE
-
-
Mashup Score: 0
An abstract is unavailable.
Source: journals.lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Courtney DiNardo, MD- Innovative Combinations of IDH Inhibitors - 7 month(s) ago
Courtney DiNardo, MD- Associate Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX Emerging as a beacon of hope in the realm of acute myeloid leukemia (AML) treatment, a new frontier is being forged through the synergistic power of innovativ…
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
AML treatment with Courtney DiNardo, MD. Combining #IDH inhibitors #ivosidenib & enasidenib with hypomethylating agents and #venetoclax precision shows promising response rates & MRD reduction. [video][slides]https://t.co/sBgNYKIi6M @_MDEducation @Ryan_fitzpatric @MDAndersonNews https://t.co/n53UUa5XHr
-
In this video, Kami J Maddocks, MD, discusses the results of a multicenter single-arm study that explored the addition of #venetoclax to #lenalidomide and #rituximab treatment for patients with previously untreated #MCL. Learn more: https://t.co/sqXKHEqdHY @kmaddmd #MedTwitter https://t.co/bYfGsyhWKm